Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by University of Chile.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
Daniel Bunout, University of Chile
ClinicalTrials.gov Identifier:
First received: March 26, 2012
Last updated: March 27, 2012
Last verified: March 2012

Biofreeze® is a topical ointment that has menthol and alcamphor. Its analgesic effect lies in the stimulation of A and C fibers by cold and nociceptive stimulation, respectively, which is produced by menthol, apparently through the newly discovered receptor TRPM8 (Transient Receptor Potential melastatin-8) The aim of this study is to investigate if BIOFREEZE ® treatment (Performance Health Inc., Export, PA) improves symptoms associated with moderate knee osteoarthritis, which would decrease the immobility and isolation in older adults.

Condition Intervention Phase
Knee Osteoarthritis
Drug: Biofreeze
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic

Resource links provided by NLM:

Further study details as provided by University of Chile:

Primary Outcome Measures:
  • WOMAC score [ Time Frame: 60 days ] [ Designated as safety issue: No ]
    WOMAC score corresponds to Western Ontario and McMaster Universities Index of Osteoarthritis

Secondary Outcome Measures:
  • Quality of life measured using SF 36 [ Time Frame: 60 days ] [ Designated as safety issue: No ]
    SF 36 correponds to a health related quality of life score

Estimated Enrollment: 50
Study Start Date: April 2012
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Biofreeze Drug: Biofreeze
Use of Biofreeze ointment
Placebo Comparator: Placebo
Use of placebo ointment
Other: Placebo
Use of placebo ointment


Ages Eligible for Study:   60 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate osteoarthritis of the knee
  • Age 60 to 80 years
  • Ambulatory

Exclusion Criteria:

  • Other conditions that affect mobility
  • Severe chronic diseases such as cardiac or renal failure
  • Cancer
  • Presence of gout
  • Cognitive impairment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01565070

Contact: Natalia Jara, MD 56 (2) 9781452 nmjara@gmail.com
Contact: Juan Berger, MSc juanignacioberger@gmail.com

Institute of Nutrition and Food Technology Not yet recruiting
Santiago, Met, Chile, 7830489
Contact: Magdalena Araya, MD    56 (2) 9781411    maraya@inta.uchile.cl   
Contact: Mauricio Gonzalez, MSc    56 (2) 9781411    mgonzale@inta.uchile.cl   
Principal Investigator: Daniel Bunout, MD         
Sub-Investigator: Natalia Jara, MD         
Sub-Investigator: Juan Berger, MSc         
Sponsors and Collaborators
University of Chile
Principal Investigator: Daniel Bunout, MD INTA University of Chile
  More Information

Responsible Party: Daniel Bunout, Medical Doctor, University of Chile
ClinicalTrials.gov Identifier: NCT01565070     History of Changes
Study First Received: March 26, 2012
Last Updated: March 27, 2012
Health Authority: Chile: Ministry of Health

Keywords provided by University of Chile:
Quality of life

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Dermatologic Agents

ClinicalTrials.gov processed this record on April 17, 2014